We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe
Read MoreHide Full Article
Mylan N.V. announced an agreement to acquire Aspen Pharmacare Holdings Limited's thrombosis business in Europe for €641.9 million.
The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names — Arixtra, Fraxiparine, Mono-Embolex and Orgaran. These products accounted for combined net sales of approximately €231 million for the 12 months ended Jun 30, 2020.
The transaction is expected to be immediately accretive to Mylan upon closing. Upon closing of the transaction, Mylan expects to fund an upfront payment of €263.2 million to Aspen from existing cash. In addition, Mylan will use the cash generated from operations to make the final deferred payment of €378.7 million on Jun 25, 2021. The closing of the proposed sale is expected to be completed before the year-end.
Aspen will retain manufacturing and product supply responsibilities and supply Mylan with finished products.
The acquisition is also expected to be accretive to Viatris upon the completion of Mylan's previously announced combination with Pfizer’s (PFE - Free Report) Upjohn that is expected to close in the fourth quarter of 2020.
The acquisition of this thrombosis portfolio will broaden Mylan's European business and make it the second-largest supplier of these products to patients in Europe. It complements and expands Mylan's complex injectables offering and presence in hospitals.
Mylan’s stock has lost 23.9% in the year so far compared with the industry’s decline of 12.6%.
Last month, the company reported second-quarter results, wherein earnings and revenues beat estimates. The coronavirus outbreak and the subsequent lockdown negatively impacted customer buying patterns. However, Wixela Inhub, the generic of GlaxoSmithKline’s (GSK - Free Report) Advair Diskus, and Yupelri, developed in collaboration with Theravance Biopharma (TBPH - Free Report) , continued to boost growth.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe
Mylan N.V. announced an agreement to acquire Aspen Pharmacare Holdings Limited's thrombosis business in Europe for €641.9 million.
The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names — Arixtra, Fraxiparine, Mono-Embolex and Orgaran. These products accounted for combined net sales of approximately €231 million for the 12 months ended Jun 30, 2020.
The transaction is expected to be immediately accretive to Mylan upon closing. Upon closing of the transaction, Mylan expects to fund an upfront payment of €263.2 million to Aspen from existing cash. In addition, Mylan will use the cash generated from operations to make the final deferred payment of €378.7 million on Jun 25, 2021. The closing of the proposed sale is expected to be completed before the year-end.
Aspen will retain manufacturing and product supply responsibilities and supply Mylan with finished products.
The acquisition is also expected to be accretive to Viatris upon the completion of Mylan's previously announced combination with Pfizer’s (PFE - Free Report) Upjohn that is expected to close in the fourth quarter of 2020.
The acquisition of this thrombosis portfolio will broaden Mylan's European business and make it the second-largest supplier of these products to patients in Europe. It complements and expands Mylan's complex injectables offering and presence in hospitals.
Mylan’s stock has lost 23.9% in the year so far compared with the industry’s decline of 12.6%.
Last month, the company reported second-quarter results, wherein earnings and revenues beat estimates. The coronavirus outbreak and the subsequent lockdown negatively impacted customer buying patterns. However, Wixela Inhub, the generic of GlaxoSmithKline’s (GSK - Free Report) Advair Diskus, and Yupelri, developed in collaboration with Theravance Biopharma (TBPH - Free Report) , continued to boost growth.
Mylan currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>